Shares of Innovent Biologics, Inc. (OTCMKTS:IVBXF – Get Free Report) rose 5.2% on Friday . The stock traded as high as $5.32 and last traded at $5.32. Approximately 790 shares traded hands during mid-day trading, a decline of 95% from the average daily volume of 15,878 shares. The stock had previously closed at $5.06.
Innovent Biologics Price Performance
The firm has a 50-day simple moving average of $4.60 and a two-hundred day simple moving average of $5.00.
About Innovent Biologics
Innovent Biologics, Inc, a biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People's Republic of China. It offers Tyvyt, a human anti-PD-1 monoclonal antibody; BYVASDA, a fully-human anti-VEGF monoclonal antibody; HALPRYZA, a recombinant chimeric murine/human anti-CD20 monoclonal antibody; SULINNO, a fully-human antiTNF-a monoclonal antibody; Pemazyre, a selective FGFR inhibitor; Olverembatinib, a novel BCR-ABL TK; Cyramza, a VEGF receptor 2 antagonist; and Retsevmo, a selective and potent RET kinase inhibitor.
Recommended Stories
- Five stocks we like better than Innovent Biologics
- What is a buyback in stocks? A comprehensive guide for investors
- How to Build the Ultimate Everything ETF Portfolio
- What is Insider Trading? What You Can Learn from Insider Trading
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- Growth Stocks: What They Are, What They Are Not
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Innovent Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovent Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
